Johnson & Johnson (NYSE:JNJ) Shares Acquired by Schnieders Capital Management LLC

Schnieders Capital Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,725 shares of the company’s stock after acquiring an additional 3,120 shares during the period. Johnson & Johnson makes up about 2.0% of Schnieders Capital Management LLC’s holdings, making the stock its 12th largest holding. Schnieders Capital Management LLC’s holdings in Johnson & Johnson were worth $10,228,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. AMF Tjanstepension AB raised its position in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $213,000. Swedbank AB lifted its position in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after acquiring an additional 111,570 shares during the last quarter. Rosenberg Matthew Hamilton grew its holdings in shares of Johnson & Johnson by 12.7% during the third quarter. Rosenberg Matthew Hamilton now owns 3,319 shares of the company’s stock worth $538,000 after purchasing an additional 374 shares during the last quarter. Finally, United Asset Strategies Inc. increased its position in shares of Johnson & Johnson by 510.6% during the third quarter. United Asset Strategies Inc. now owns 60,192 shares of the company’s stock worth $9,755,000 after purchasing an additional 50,334 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Leerink Partners reduced their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Finally, Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ opened at $165.23 on Friday. The firm’s 50-day moving average is $150.90 and its two-hundred day moving average is $156.04. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $397.81 billion, a P/E ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the business posted $2.29 EPS. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.